Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more
Ikonisys SA (ALIKO) - Net Assets
Latest net assets as of June 2025: €19.04 Million EUR
Based on the latest financial reports, Ikonisys SA (ALIKO) has net assets worth €19.04 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€26.54 Million) and total liabilities (€7.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.04 Million |
| % of Total Assets | 71.74% |
| Annual Growth Rate | 18.53% |
| 5-Year Change | 150.05% |
| 10-Year Change | N/A |
| Growth Volatility | 104.33 |
Ikonisys SA - Net Assets Trend (2019–2024)
This chart illustrates how Ikonisys SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ikonisys SA (2019–2024)
The table below shows the annual net assets of Ikonisys SA from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €14.25 Million | -9.42% |
| 2023-12-31 | €15.73 Million | -10.97% |
| 2022-12-31 | €17.67 Million | -11.70% |
| 2021-12-31 | €20.01 Million | +251.17% |
| 2020-12-31 | €5.70 Million | -6.39% |
| 2019-12-31 | €6.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ikonisys SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9578730400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €22.78 Million | 159.84% |
| Total Equity | €14.25 Million | 100.00% |
Ikonisys SA Competitors by Market Cap
The table below lists competitors of Ikonisys SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
23Andme Holding Co
NASDAQ:ME
|
$9.76 Million |
|
JET Optoelectronics Co., Ltd.
TWO:2255
|
$9.76 Million |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
$9.77 Million |
|
Catskill Hudson Bancorp Inc
PINK:CSKL
|
$9.77 Million |
|
Massimo Group Common Stock
NASDAQ:MAMO
|
$9.76 Million |
|
We Buy Cars Hlds Ltd
JSE:WBC
|
$9.76 Million |
|
Homeritz Corporation Bhd
KLSE:5160
|
$9.76 Million |
|
Jioushun Construction Co., Ltd.
TWO:5547
|
$9.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ikonisys SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,732,640 to 14,250,703, a change of -1,481,937 (-9.4%).
- Net loss of 3,239,970 reduced equity.
- Other comprehensive income increased equity by 44,127.
- Other factors increased equity by 1,713,906.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.24 Million | -22.74% |
| Other Comprehensive Income | €44.13K | +0.31% |
| Other Changes | €1.71 Million | +12.03% |
| Total Change | €- | -9.42% |
Book Value vs Market Value Analysis
This analysis compares Ikonisys SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.36x to 1.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.63 | €1.48 | x |
| 2020-12-31 | €0.59 | €1.48 | x |
| 2021-12-31 | €2.11 | €1.48 | x |
| 2022-12-31 | €1.86 | €1.48 | x |
| 2023-12-31 | €1.51 | €1.48 | x |
| 2024-12-31 | €1.27 | €1.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ikonisys SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -320.44%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.92x
- Recent ROE (-22.74%) is below the historical average (-18.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -30.86% | -2745.62% | 0.01x | 1.34x | €-2.49 Million |
| 2020 | -27.59% | -1575.00% | 0.01x | 1.42x | €-2.14 Million |
| 2021 | -2.85% | -156.45% | 0.02x | 1.13x | €-2.57 Million |
| 2022 | -13.85% | -261.79% | 0.04x | 1.23x | €-4.22 Million |
| 2023 | -14.41% | -505.54% | 0.02x | 1.33x | €-3.84 Million |
| 2024 | -22.74% | -320.44% | 0.04x | 1.92x | €-4.67 Million |
Industry Comparison
This section compares Ikonisys SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $34,949,259
- Average return on equity (ROE) among peers: -36.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ikonisys SA (ALIKO) | €19.04 Million | -30.86% | 0.39x | $9.76 Million |
| Affluent Medical SAS (AFME) | $33.83 Million | -45.01% | 0.77x | $31.64 Million |
| Biosynex (ALBIO) | $124.31 Million | -29.72% | 0.94x | $7.06 Million |
| Bluelinea SA (ALBLU) | $1.96 Million | -41.72% | 0.71x | $6.02 Million |
| Carmat (ALCAR) | $-43.76 Million | 0.00% | 0.00x | $3.28 Million |
| Diagnostic Medical Systems SA (ALDMS) | $13.72 Million | -36.04% | 2.73x | $13.39 Million |
| Eurobio Scientific SA (ALERS) | $175.17 Million | 2.76% | 0.81x | $5.52 Million |
| Implanet SA (ALIMP) | $3.54 Million | -99.97% | 3.09x | $6.96 Million |
| Mediantechn (ALMDT) | $0.00 | 0.00% | 0.00x | $86.92 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.70 Million |